eligibility_summary
Eligible: histologic/cytologic gastroesophageal or gastric adenocarcinoma with measurable disease (RECIST 1.1) and adequate organ function, contraception required. Exclude: recent anticancer/PD‑1/PD‑L1/investigational therapy, untreated brain mets (treated/stable allowed), HIV, active HBV/HCV, significant autoimmune disease (some stable exceptions), pneumonitis needing steroids/current, prior organ/allogeneic transplant, major surgery <28 days, pregnant/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Personalized neoantigen vaccine (biologic), created from each patient’s tumor mutations to elicit anti-tumor immunity, and nivolumab (Opdivo), an anti–PD-1 IgG4 monoclonal antibody immune checkpoint inhibitor. Mechanisms: The vaccine promotes dendritic cell presentation of patient-specific neoantigen peptides via MHC, priming and expanding tumor-specific CD8+ cytotoxic and CD4+ helper T cells and generating immune memory. Nivolumab blocks the PD-1/PD-L1 inhibitory pathway on T cells, reversing exhaustion and restoring effector function. Targets/pathways: Dendritic cells and antigen-presenting cells, effector and memory T cells, neoantigen–TCR recognition, MHC class I/II antigen presentation, PD-1 checkpoint signaling. Indication: upper GI (gastroesophageal/gastric) cancers. Trial status: Withdrawn (funding).